Cohance Lifesciences profit and loss

Latest FY26

Revenue: ₹2,269cr+89.4% on FY25
EBITDA: ₹427cr+13.8% on FY25
Net profit: ₹150cr−43.3% on FY25
EPS: ₹4.69−55.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,142	2,269	1,198	1,051	1,340	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	32.2	34.1	58.6	61.9	46.4
	2,174	2,303	1,256	1,113	1,387
	686	705	223	266	430
	−51.0	−42.8	82.6	49.2	−20.9
	507	508	250	136	111
	33.8	37.2	12.4	7.5	5.4
	192	187	77.5	54.6	47.7
	683	671	268	195	254
	2,051	2,066	912	708	827
	316	427	375	406	567
	124	240	298	351	519
Profit
	123	237	344	406	560
	−21.4	−29.5	0.0	0.0	0.0
	101	207	344	406	560
	63.9	79.9	93.3	98.8	144
	−21.0	−23.0	−14.2	6.6	4.3
	42.9	56.9	79.2	105	148
	58.5	150	265	300	411
	58.5	150	265	300	411
	105	99.0	13.1	13.2	−0.2
	163	249	278	313	411
	106	179	268	300	—
	−47.7	−29.1	−3.1	0.0	—
Per share
	₹2.78	₹4.69	₹10.52	₹11.80	₹16.16
	₹2.74	₹4.68	₹10.45	₹11.80	₹16.16
Other comprehensive income — detail
	105	99.0	13.1	—	—
	96.9	96.8	8.9	0.1	−0.3
	26.6	26.6	2.6	—	—
	—	—	—	−0.1	−0.1
	34.1	26.3	6.8	13.0	—
	−0.5	−2.5	0.0	—	—
	204	271	280	—	—
	−40.2	−21.5	−2.5	—	—
Per share — as-filed variants
	₹2.78	₹4.69	₹10.52	₹11.80	₹16.16
	₹2.74	₹4.68	₹10.45	₹11.80	₹16.16
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,507	1,606	892	736	931
	70.4%	70.8%	74.5%	70.0%	69.5%
Adjusted (ex-exceptional items) — derived
	123	237	344	406	560
	−21.4	−29.5	0.0	0.0	0.0
	70.9	171	265	300	411
	₹3.37	₹5.36	₹10.52	₹11.80	₹16.16

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

COHANCE₹481.35

Cohance Lifesciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB SYNGENE ASTERDM LALPATHLAB NATCOPHARM WOCKPHARMA NEULANDLAB NHMcap ₹18,416 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,340.3	1,051.4	1,197.6	2,268.6	2,141.5
Other Income	46.4	61.9	58.6	34.1	32.2
Total Income	1,386.7	1,113.3	1,256.1	2,302.6	2,173.7
Expenses
+ Cost of Materials Consumed	430.1	265.9	222.7	705.4	685.7
+ Changes in Inventories	-20.9	49.2	82.6	-42.8	-51.0
+ Employee Benefit Expense	110.5	135.9	249.6	507.7	507.4
+ Finance Costs	5.4	7.5	12.4	37.2	33.8
+ Depreciation & Amortisation	47.7	54.6	77.5	187.3	191.7
+ Other Expenses	254.1	194.6	267.5	671.2	683.2
Total Expenses	827.0	707.6	912.2	2,066.1	2,050.9
EBITDA	566.5	405.8	375.2	427.0	316.1
EBIT	518.8	351.2	297.7	239.7	124.4
Profit
PBT before Exceptional Items	559.7	405.7	343.9	236.5	122.8
+ Exceptional Items	0.0	0.0	0.0	-29.5	-21.4
Pretax Income	559.7	405.7	343.9	207.0	101.4
+ Current Tax	144.1	98.8	93.3	79.9	63.9
+ Deferred Tax	4.3	6.6	-14.2	-23.0	-21.0
Tax Expense	148.4	105.4	79.2	56.9	42.9
Net Income	411.3	300.3	264.8	150.1	58.5
+ Net Income — Continuing Ops	411.3	300.3	264.8	150.1	58.5
+ Other Comprehensive Income	-0.2	13.2	13.1	99.0	104.9
Total Comprehensive Income	411.1	313.5	277.9	249.2	163.4
Net Income to Common	—	300.3	267.9	179.2	106.2
Minority Interest	—	0.0	-3.1	-29.1	-47.7
Per Share
Basic EPS	16.16	11.80	10.52	4.69	2.78
Diluted EPS	16.16	11.80	10.45	4.68	2.74
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	13.1	99.0	104.9
+ Items NOT to be Reclassified to P&L	-0.3	0.1	8.9	96.8	96.9
+ Tax on Items NOT to be Reclassified	—	—	2.6	26.6	26.6
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.1	—	—	—
+ Items to be Reclassified to P&L	—	13.0	6.8	26.3	34.1
+ Tax on Items to be Reclassified	—	—	0.0	-2.5	-0.5
Comprehensive Income — Owners of Parent	—	—	280.4	270.7	203.6
Comprehensive Income — Non-controlling Interests	—	—	-2.5	-21.5	-40.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	16.16	11.80	10.52	4.69	2.78
Diluted EPS — Continuing Operations	16.16	11.80	10.45	4.68	2.74
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	931.2	736.3	892.3	1,605.9	1,506.7
Gross Margin %	69.48	70.04	74.51	70.79	70.36
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	559.7	405.7	343.9	236.5	122.8
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-29.5	-21.4
Net Income Adj (tax-effected)	411.3	300.3	264.8	171.5	70.9
EPS Adj	16.16	11.80	10.52	5.36	3.37
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	25.5	25.5	25.5	38.3	38.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.